Medicinal chemistry of target family-directed masterkeys

Drug Discovery Today

Volumn 8, Issue 15, 2003, Pages 681-691

  Müller, Gerhard ^a  

^a Axxima Pharmaceuticals AG   (Germany)

Author keywords

Drug design; Druggable genome; Medicinal chemistry; Molecular masterkey; Molecular recognition; Privileged structures; Target families; Target family biased chemistry

Indexed keywords

BETA1A INTERFERON; CELECOXIB; DEXMETHYLPHENIDATE; DOPAMINE UPTAKE INHIBITOR; DOXORUBICIN; DROTRECOGIN; ERTAPENEM; ESCITALOPRAM; EZETIMIBE; FAMOTIDINE; FONDAPARINUX; FORMOTEROL FUMARATE; FULVESTRANT; G PROTEIN COUPLED RECEPTOR; GEFITINIB; GRANISETRON; ICODULINE; IMATINIB; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OXALIPLATIN; PARATHYROID HORMONE[1-34]; PIMECROLIMUS; PRAMIPEXOLE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIMONABANT; ROFECOXIB; TEGASEROD; UNINDEXED DRUG; UNIPROST; VALDECOXIB; VORICONAZOLE; ZOLEDRONIC ACID;

DRUG APPROVAL; DRUG INDUSTRY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; NUCLEAR MAGNETIC RESONANCE; REVIEW;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS;

EID: 0042121318     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(03)02781-8     Document Type: Review

References (41)

1. Drews J. Drug discovery: a historical perspective. Science. 287:2000;1960-1963.
2. Drews J. Quest of Tomorrow's Medicines. 1998;Springer Verlag.
3. Drews J. Drug Discovery Today - and Tomorrow. Drug Discov. Today. 5:2000;2-4.
4. Drews J. Strategic trends in the drug industry. Drug Discov. Today. 8:2003;411-420.
5. Thayer A.M. Major drug firms eke out increases. Chem. Eng. News. 81:2003;13-14.
6. Drews J. Genomic sciences and the medicine of tomorrow. Nat. Biotechnol. 14:1996;1516-1518.
7. Drews J., Ryser S. Innovation deficit in the pharmaceutical industry. Drug Inf. J. 30:1996;97-108.
8. Drews J., Ryser S. The role of innovation in drug development. Nat. Biotechnol. 15:1997;1318-1319.
9. Bolten B.M., DeGregorio T. Trends in development cycles. Nat. Rev. Drug Discov. 1:2002;335-336.
10. Miller H.I. As Biotech turns 20. Nat. Rev. Drug Discov. 1:2002;1007-1008.
11. Tufts Center for the Study of Drug Development (2002) Outlook 2002, Boston.
12. Dolle R.E. Comprehensive survey of combinatorial library synthesis. J. Comb. Chem. 4:2002;369-418.
13. Tollman, P. et al. (2001) A Revolution in R&D: How Genomics and Genetics are transforming the Biopharmaceutical Industry. ( http://www.bcg.com/publications/files/eng_genomicsgenetics_rep_11_01.pdf ).
14. Collins F.S., et al. New goals for the U.S. Human Genome Project: 1998-2003. Science. 282:1998;682-689.
15. Szymkowski D.E. Too many targets, not enough target validation. Drug Discov. Today. 6:2001;398-399.
16. Lipinski C., et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46:2001;3-26.
17. Hopkins A.L., Groom C.R. The druggable genome. Nat. Rev. Drug Discov. 1:2002;727-730.
18. Evans B.E., et al. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J. Med. Chem. 31:1988;2235-2246.
19. Patchett A.A., Nargund R.P. Privileged structures - an update. Annu. Rep. Med. Chem. 35:2000;289-298.
20. Chang R.S., et al. Tifluadom, a kappa-opiate agonist, acts as a peripheral cholecystokinin receptor antagonist. Neurosci. Lett. 72:1986;211-214.
21. Roemer D., et al. An opioid benzodiazepine. Nature. 298:1982;759-760.
22. Roche O., et al. Development of a virtual screening method for identification of 'Frequent Hitters' in compound libraries. J. Med. Chem. 45:2002;137-142.
23. McGovern S.L., et al. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J. Med. Chem. 45:2002;1712-1722.
24. McGovern S.L., Shoichet B.K. Kinase inhibitors: not just for kinases anymore. J. Med. Chem. 46:2003;1478-1483.
25. Bemis G.W., Murcko M.A. The properties of known drugs. 1. Molecular frameworks. J. Med. Chem. 39:1996;2887-2893.
26. Bemis G.W., Murcko M.A. Properties of known drugs. 2. Side chains. J. Med. Chem. 42:1999;5095-5099.
27. Lewell X.Q., et al. RECAP - retrosynthetic combinatorial analysis procedure: a powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry. J. Chem. Inf. Comput. Sci. 38:1998;511-522.
28. Hajduk P.J., et al. Privileged molecules for protein binding identified from NMR-based screening. J. Med. Chem. 43:2000;3443-3447.
29. Willoughby C.A., et al. Combinatorial synthesis of 3-(Amidoalkyl) and 3-(Aminoalkyl)-2-arylindole derivatives: discovery of potent ligands for a variety of G protein-coupled receptors. Bioorg. Med. Chem. Lett. 12:2002;93-96.
30. Weir M.P., et al. Novel natural product 5,5-trans-lactone inhibitors of human α-thrombin: mechanism of action and structural studies. Biochemistry. 37:1998;6645-6657.
31. O'Neill M.J., et al. Isolation of translactone-containing triterpenes with thrombin inhibitory activities from the leaves of lantana camara. J. Nat. Prod. 61:1998;1328-1331.
32. Teague S.J., et al. The design of leadlike combinatorial libraries. Angew. Chem. Int. Ed. Engl. 38:1999;3743-3748.
33. Finch H., et al. 5,5-trans lactone-containing inhibitors for serine proteases identification of a novel, acylating thrombin inhibitor. Bioorg. Med. Chem. Lett. 8:1998;2955-2960.
34. Pass M., et al. Thrombin inhibitors based on 5,5 trans-fused indane lactams. Bioorg. Med. Chem. Lett. 9:1999;1657-1662.
35. MacDonald S.J.F., et al. The discovery of a potent, intracellular, orally bioavailable, long duration inhibitor of human neutrophil elastase-GW311616A a development candidate. Bioorg. Med. Chem. Lett. 11:2001;895-898.
36. MacDonald S.J.F., et al. Discovery of further pyrrolidine trans-lactams as inhibitors of human neutrophil elastase (HNE) with potential as development candidates and the crystal structure of HNE complexed with an inhibitor (GW475151). J. Med. Chem. 45:2002;3878-3890.
37. Borthwick A.D., et al. Design and synthesis of pyrrolidine-5,5-trans-lactams (5-Oxo-hexahydro-pyrrolo3,2-bpyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 1. The α-methyl-trans-lactam template. J. Med. Chem. 43:2000;4452-4464.
38. Borthwick A.D., et al. Design and synthesis of pyrrolidine-5,5-trans-lactams (5-Oxo-hexahydro-pyrrolo3,2-bpyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 2. Potency and Chirality. J. Med. Chem. 45:2002;1-18.
39. Andrews D.M., et al. Pyrrolidine-5,5-trans-lactams. 1. Synthesis and incorporation into inhibitors of hepatitis C Virus NS3/4A protease. Org. Lett. 4:2002;4475-4478.
40. Andrews D.M., et al. Pyrrolidine-5,5-trans-lactams. 2. The use of x-ray crystal structure data in the optimization of P3 and P4 substituents. Org. Lett. 4:2002;4479-4482.
41. Wess G., et al. Medicinal chemistry: challenges and opportunities. Angew. Chem. Int. Ed. Engl. 40:2001;3341-3350.